Search PubMed⌕ Search

Biomedical subjects

D L Murphy

Publications and source records attributed to D L Murphy.

At least 433 records · Page 24Linked to original sources
PubMed1981

Applicability of models for carrier-mediated serotonin transport to pools of serotonin in intact human platelets.

Intact human platelets can accumulate serotonin (5HT) in compartments which are vesicular (thrombin-releasable) or extra-vesicular (non-thrombin-releasable). 1. The net accumulation of extracellular 5HT in either compartment is not coupled in a reciprocal fashion to the presence of appropriate sodium gradients across the cell plasma membrane, and 5HT already present in either compartment is not removed when trans-membrane sodium gradients are abolished or reversed. 2. Net counter-transport of 5HT in either compartment is not detectable. 3. The data are not consistent with transport models such as that for glucose in which appropriate sodium gradients produce gradients of a co-transported molecule, or with models in which counter-transport can occur.

Biological Transport↗
PubMed1981

The dexamethasone suppression test as a measure of hypothalamic-pituitary feedback sensitivity and its relationship to behavioral arousal.

A nonhuman primate model was used to evaluate the value of the dexamethasone suppression test as an index of hypothalamic-pituitary-adrenal responsiveness to arousal. In 8 rhesus monkeys plasma cortisol was suppressed by dexamethasone in a dose-dependent fashion at doses between 0.75 and 33 microgram/kg. A replication study was performed 5 months later using a single dexamethasone dose (17 microgram/kg) known to produce maximal plasma cortisol suppression. This yielded highly correlated results (r = 0.91, p less than 0.005) suggesting that dexamethasone suppressibility may be a stable characteristic of individual animals. In 9 other animals whose arousal responses to a stressful procedure (nasogastric tube insertion) had been rated daily over a previous 3-month period, baseline plasma cortisol levels and the percent suppression of plasma cortisol by dexamethasone were evaluated. Baseline plasma cortisol levels did not significantly correlate with the degree of dexamethasone-suppression and the mean arousal ratings within animals. However, the postdexamethasone percent of baseline cortisol did correlate significantly (r = 0.75, p less than 0.025) with individual mean arousal ratings. These preliminary results suggest that assessment of the sensitivity of an individual's hypothalamic-pituitary glucocorticoid feedback system may be a better predictor than its baseline cortisol concentrations of its degree of behavioral arousal to stress.

Animals↗
PubMed1981

Childhood obsessive-compulsive disorder.

The authors collected clinical diagnostic, neurophysiological, electrophysiological, and biochemical data on 9 adolescents who had primary obsessive-compulsive disorder. The results indicate considerable descriptive validity of the syndrome in childhood and its independence from obsessional traits; however, all of the children had a history of major depressive disorder, and their sleep EEG measures resembled those of young adults with primary depressive disorder. The patients' families did not have a more consistent pattern of anxiety disorder or any other psychiatric disorder than do families of adult obsessive patients. Psycholinguistic test results showed a lack of normal laterality, which has been reported for other psychiatric illness.

Adolescent↗
PubMed1981

Diurnal variation in cerebrospinal fluid prolactin concentration of the rhesus monkey.

PRL immunoreactivity in the cerebrospinal fluid (CSF) of the rhesus monkey was found found to undergo a diurnal variation. Hourly samples of CSF from four adult male rhesus monkeys showed a mean peak PRL immunoreactivity of 6.30 +/- 2.53 ng/ml at 0200 h and a mean minimum concentration at 1500 h of 3.15 +/- .68 ng/ml. To our knowledge, this is the first report of a significant diurnal variation in the concentration of an anterior pituitary peptide hormone in CSF.

Animals↗
PubMed1981

Deprenyl in Parkinson disease.

(-)Deprenyl, a specific monoamine oxidase subtype B inhibitor (MAOI-B), has been reported to be a safe and valuable adjunct to conventional treatment of parkinsonism. A double-blind, clinical comparison of (-)deprenyl with placebo was undertaken in 11 parkinsonian patients; the efficacy of 10 mg daily was studied over 4 weeks. In four cases the clinical score for parkinsonian deficits improved during deprenyl therapy, and in five it deteriorated; there was no change in one patient. Two subjects failed to complete the study. (-)Deprenyl induced euphoria and insomnia. It was concluded that any advantages deriving from the use of (-)deprenyl in parkinsonism are limited, and probably dominated by its elevation of mood. Biochemical analysis failed to reveal any significant increase in platelet or plasma catecholamine concentrations during deprenyl therapy. There was, however, a significant decrease in plasma epinephrine (p < 0.05) and platelet MAO activity (p < 0.005).

Adult↗
PubMed1981

Lithium and mood change in affective disorder patients.

The authors evaluated whether the dysphoric effects reported by normals given lithium in several recent studies might also be found in depressed patients if detailed self-ratings were used in a double-blind study design. Nine depressed patients were studied at the end of lithium and placebo treatment trials. No overall adverse effects of lithium were found for the entire group, but individuals showed significant inverse correlations between pretreatment dysphoria and depression and the development of these symptoms with lithium, i.e., the less dysphoric and depressed patients (the more "normal" individuals) did report more adverse symptoms while the patients with higher initial symptom scores rated themselves as improved.

Adult↗
PubMed1980

Mood and behavioral effects of physostigmine on humans are accompanied by elevations in plasma beta-endorphin and cortisol.

Administration of physostigmine to normal volunteers produced significant elevations in plasma cortisol and beta-endorphin immunoreactivity as well as alterations in mood, cognition, and behavior. These observations might be explained by a cholinergically mediated stress syndrome. However, peak elevations in plasma beta-endorphin immunoreactivity (but not in plasma cortisol) were significantly correlated with physostigmine-induced increases in depression ratings. These results suggest that a cholinergically mediated beta-endorphin pathway may be involved in the observed affective changes.

Behavior↗
PubMed1980

Dexamethasone fails to suppress beta-endorphin plasma concentrations in humans and rhesus monkeys.

In humans and rhesus monkeys, dexamethasone decreased concentrations of plasma cortisol but did not alter circulating beta-endorphin immunoreactivity. Contrary to current theory suggesting that pituitary beta-endorphin and adrenocorticotropic hormone are controlled by identical regulatory mechanisms for synthesis and release, our evidence suggests that in higher primates the established glucocorticoid feedback mechanism for the adrenocorticotropic hormone-cortisol system does not regulate beta-endorphin secretion in the same way.

Adrenocorticotropic Hormone↗
PubMed1980

Psychiatric vulnerability, monoamine oxidase, and the average evoked potential.

College students in two separate studies had platelet monoamine oxidase (MAO) activity determinations and average evoked potential (AEP) measurements taken. On the basis of Minnesota Muliphasic Personality Inventory (MMPI) or Research Diagnostic Criteria (RDC) evaluations, psychopathology, particularly affective disorder, was found to be more prevalent among both persons with the combination of low MAO activity and AEP augmenting and those with high MAO activity and AEP reducing. The same pattern is apparent whether students were selected for extremely high or low MAO activity (study 1) or for elevated or normal MMPI scores (study 2). Some psychiatric patient groups also show this pattern. An interactive model of sensation-seeking and sensory inhibition is presented.

Adolescent↗
PubMed1980

Denial and somatization as characteristics of bipolar depressed groups.

A group of 104 depressed patients (54 bipolar and 50 unipolar) completed the booklet form of the MMPI. In addition to the usual validity and clinical scales of the MMPI, 55 special scales, selected for relevancy to the affective disorders, also were included in the study. Inspection of the 11 of 68 MMPI scales on which the biopolar group had significantly higher mean scores than the unipolar group disclosed a patterning of scales suggestive of the use of denial and somatization. These results, coupled with those of other recent studies, suggest that socially desirable response sets and the use of denial and somatization on the MMPI are adaptive defenses in bipolar depressed groups.

Attention↗